CinCor Pharma, Inc.'s stock is down 5.5%, but insiders still have about US$213k in profit after buying earlier this year

Insiders who bought CinCor Pharma, Inc. (NASDAQ:CINC) in the last 12 months may probably not pay attention to the stock's recent 5.5% drop. After taking the recent loss into consideration, the US$279k worth of stock they bought is now worth US$492k, indicating that their investment yielded a positive return.

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

If you're not interested in researching CINC's insider transactions, we have a free list of interesting investing ideas to potentially inspire your next investment!

CinCor Pharma Insider Transactions Over The Last Year

The CEO & Director Marc M. de Garidel made the biggest insider purchase in the last 12 months. That single transaction was for US$200k worth of shares at a price of US$16.00 each. Even though the purchase was made at a significantly lower price than the recent price (US$28.22), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

In the last twelve months CinCor Pharma insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership Of CinCor Pharma

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. It appears that CinCor Pharma insiders own 1.6% of the company, worth about US$19m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

What Might The Insider Transactions At CinCor Pharma Tell Us?

The fact that there have been no CinCor Pharma insider transactions recently certainly doesn't bother us. However, our analysis of transactions over the last year is heartening. Insiders do have a stake in CinCor Pharma and their transactions don't cause us concern. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. At Simply Wall St, we've found that CinCor Pharma has 3 warning signs (2 don't sit too well with us!) that deserve your attention before going any further with your analysis.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.